Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development
Key Highlights
- ➤Harvey Spevak appointed Vesalius Chairman, effective November 13, 2026
- ➤US$6.5 million strategic financing led by Harvey Spevak preceded appointment
- ➤Exclusive Celularity partnership establishes U.S. peptide API manufacturing platform
- ➤Peptide therapeutics market projected to reach US$295 billion by 2033
- ➤Vesalius supplies peptide products across a significant global provider network
Expert Statements
Harvey Spevak, Chairman of Vesalius
“I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade”
Harvey Spevak, Chairman of Vesalius
“Vesalius has an ambitious vision for building a differentiated global platform. I'm excited to work with the Board and management team, bringing my experience in building consumer-focused brands, driving innovation and creating long-term value to help shape the company's next phase of growth.”
David Adelman, Director of Vesalius
“On behalf of the Board, I am pleased to welcome Harvey as Chairman”
David Adelman, Director of Vesalius
“He joins a group of directors whose experience across health, finance, media and consumer brands has already helped shape Vesalius into the company it is today. With Harvey leading the Board, we are well positioned as Vesalius scales globally.”
Kevin Mayer, Director of Vesalius
“Vesalius is well positioned to help shape the future of peptides and longevity, with high-quality products, a growing provider network and significant opportunity to scale”
Kevin Mayer, Director of Vesalius
“Our ambition is to build a category-defining brand that earns the trust of providers and patients alike. I have known Harvey for many years, his leadership and strategic vision are exceptionally strong. Harvey has a proven track record of building an iconic brand and transforming an industry, and his leadership will be invaluable as we realize Vesalius's full potential.”
Appointment Follows US$6.5 Million Strategic Financing and Strengthens Board Leadership Alongside David Adelman, Kevin Mayer, Lee Applbaum and James McRoberts
Vancouver, British Columbia and Scottsdale, Arizona--(Newsfile Corp. - November 13, 2026) - Vesalius Longevity Labs Inc. (CSE: VLAB)("Vesalius" or the "Company"), a leading global peptide and longevity company, today announced the appointment of Harvey Spevak, as Chairman of its Board of Directors, effective November 13, 2026. The appointment follows a US$6.5 million financing led by Mr. Spevak, who brings a globally recognized leader in the wellness space to Vesalius as interest in longevity and proactive health continues to accelerate.
Get started
Create a free account to read the full story.